meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA)
1
es-BC - HER2 positive - (neo)adjuvant (NA)
4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
5
la/mBC - HER2 positive - 2nd Line (L2)
13
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
HER inhibitor
HER2 inhibitor
trastuzumab based treatment
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
versus all
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus endocrine therapy
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antibody–drug conjugate
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
es-BC - HER2 positive - (neo)adjuvant (NA)
4
Comparator:
vs trastuzumab;
vs trastuzumab plus endocrine therapy;
Risk of bias:
low;
some concerns;
high;
NA;